Table 2.
Statistical significance of 10-year OS as a function of the PITX2 cutoff
| Cutoff applieda | Cohort 1: untreated TNBC |
Cohort 2: ANT-treated TNBC |
||
|---|---|---|---|---|
| 10-year OS HR | p value | 10-year OS HR |
p value | |
| PMR 0 | 1.50 | 0.280 | 2.29 | 0.125 |
| PMR 1 | 0.52 | 0.172 | 3.65 | 0.017 |
| PMR 2 | 1.55 | 0.259 | 3.96 | 0.011 |
| PMR 3–18 | 0.48–2.05 | 0.119–0.505 | 2.98–4.11 | 0.009–0.041 |
| PMR 19 | 2.05 | 0.119 | 5.31 | 0.003 |
| PMR 20–23 | 0.68–2.57 | 0.056–0.169 | 5.44 | 0.005 |
| PMR 24–26 | 2.57 | 0.056 | 6.51 | 0.002 |
| PMR 27 | 4.33 | 0.007 | 6.51 | 0.002 |
a
≤ vs. > cutoff PMR value applied in cohorts 1 and 2. ANT, anthracycline-based chemotherapy; OS, overall-survival.